Psychiatry, Mental Health and Addictions

The Psychiatry, Mental Health and Addictions Research Group at the Vall d\\\’Hebron Research Institute is a multidisciplinary team that over the past 15 years has focused its scientific activity on the research (both nationally and internationally) of clinical, therapeutic and etiopathogenic aspects of: Neurodevelopmental Disorders (especially Attention-Deficit / Hyperactivity Disorder, Autism and Fetal Alcohol Syndrome); Personality Disorders (especially Borderline Personality Disorder); Addictive behaviours (especially Dual Pathology and Smoking); Transcultural Psychiatry; Interconsultation and Liaison Psychiatry; Resistant Major Depressive Disorder; Perinatal psychiatry; and Child sexual abuse and maltreatment. At international level, it participates and/or coordinates several European projects of great repercussion in the area of mental health. And at national level, it is the group 27 of the CIBERSAM (Centre for Biomedical Research in Mental Health Network-G27).

eCORE

Brain & Mind and Behaviour
Woman & Child Health & Rare Diseases

Team

Group Leader
Josep Antoni Ramos-Quiroga

Principal Investigator (PI)
Marta Ribasés Haro, Anna Beneria González, Mª Dolores Braquehais Conesa, Eugeni Bruguera Cortada, Natalia Calvo Piñero, Francisco Collazos Sanchez, Marc Ferrer Vinardell, Sara Guila Fidel Kinori, Núria Gómez Barros, Lara Grau Lopez, Carlos Jacas Escarcellé, Pilar Lusilla Palacios, José Antonio Navarro Sanchís, Gemma Parramon Puig, Marta Quesada Franco, Vanesa Richarte Fernández, Amanda Rodríguez Urrutia, María Soler, Christian Fadeuilhe, Laura Gisbert

Researchers
Silvia Alemany Sierra, Dimitra Tatiana Anastasiadou, Mª Sonsoles Cepeda Diez, Raquel Vidal Estrada, Silvia Amoretti, Jorge Lugo Marin, Gemma Nieva Rifa, Elena Ros, Constanza Daigré, Montserrat Corrales, Gara Arteaga Henriquez, Laura Maran, Gemma Español

PhD Students
Christina Regales Peco, Miguel Angel Sandonis Vicente, Pedro Serrano Pérez, Felipe Palma, Natàlia Llonga

Lab Technicians
Pau Carabí Gassol, Valeria Macias Chimborazo

Nursing and Technical Staff
Montserrat Fabregat Garcia, Pol Ibañez Jimenez, Estela García Egea, Judit Palacio Sanchez, Carolina Ramos Sayalero, Imanol Setien Ramos, Silvia Muñoz, Àlex Rué Jiménez, Berta Roig, Sara Fernandez Torrelles, Raquel Ibarz López

Publications

67.2

%Q1

407.60

Impact Factor

7.03

Average Impact Factor

Serrano-Pérez P, Rivero-Santana A, Daigre-Blanco C, Palma-Álvarez RF, Nistal-Franco I, Antoni Ramos-Quiroga J, Grau-López L.
Shared decision making in patients with substance use disorders: A one-year follow-up study
Psychiatry Res. 2023 Nov;329:115540.
DOI: 10.1016/j.psychres.2023.115540
IF: 11.3

Cabana-Domínguez J, Llonga N, Arribas L, Alemany S, Vilar-Ribó L, Demontis D, Fadeuilhe C, Corrales M, Richarte V, Børglum AD, Ramos-Quiroga JA, Soler Artigas M, Ribasés M.
Transcriptomic risk scores for attention deficit/hyperactivity disorder.
Mol Psychiatry. 2023 Aug;28(8):3493-3502
DOI: 10.1038/s41380-023-02200-1.
IF: 13.437

Alemany S, Soler-Artigas M, Cabana-Domínguez J, Fakhreddine D, Llonga N, Vilar-Ribó L, Rodríguez-Urrutia A, Palacio J, González-Castro AM, Lobo B, Alonso-Cotoner C, Simrén M, Santos J, Ramos-Quiroga JA, Ribasés M.
Genome-wide multi-trait analysis of irritable bowel syndrome and related mental conditions identifies 38 new independent variants.
J Transl Med. 2023 Apr 21;21(1):272.
DOI: 10.1186/s12967-023-04107-5
IF: 7.4

Vilar-Ribó L, Cabana-Domínguez J, Martorell L, Ramos-Quiroga JA, Sanchez-Roige S, Palmer AA, Vilella E, Ribasés M, Muntané G, Soler Artigas M
Shared genetic architecture between attention-deficit/hyperactivity disorder and lifespan.
Neuropsychopharmacology. 2023 Jun;48(7):981-990
DOI: 10.1038/s41386-023-01555-x.
IF: 7.6

Palma-Álvarez RF, Daigre C, Ros-Cucurull E, Perea-Ortueta M, Ortega-Hernández G, Ríos-Landeo A, Roncero C, Ramos-Quiroga JA, Grau-López L.
Clinical features and factors related to lifetime suicidal ideation and suicide attempts in patients who have had substance-induced psychosis across their lifetime
Psychiatry Res. 2023 May;323:115147.
DOI: 10.1016/j.psychres.2023.115147
IF: 11.3

Projects

TIMESPAN: Management of chronic cardiometabolic disease and treatment discontinuity in adult ADHD patients
Principal Investigator: Josep Antoni Ramos-Quiroga
Agency: International European Comission (Horizon 2020)
Funding: 499,986 €
Period: 2021-2025

DynAMoND – Dinámica de la modulación afectiva en los trastornos del neurodesarrollo.
Principal Investigator: Josep Antoni Ramos-Quiroga
Agency: NEURON BIOPHARMA, S.A.; Instituto de Salud Carlos III.
Funding: 174,845 €
Period: 2022-2025

DISCOvERIE: Development, dIagnosis and prevention of gender-related Somatic and mental COmorbiditiEs in iRrItable bowel syndrome in Europe.
Principal Investigator: Josep Antoni Ramos-Quiroga
Agency: European Commission. Horizon 2020
Funding: 1,147,462.5 €
Period: 2020 - 2024

Estudio de asociación a escala transcriptómica (TWAS) en el Trastorno por Déficit de Atención con Hiperactividad (TDAH)
Principal Investigator: Marta Ribasés Haro
Agency: Fondo de Investigación Sanitaria (FIS), Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (MICINN)
Funding: 190,877.50€
Period: 2021-2024

Modelos predictivos basados en datos genéticos, transcriptómicos y de micro ARN para el estudio del TDAH: un enfoque multiómico.
Principal Investigator: María Soler/ J. Antoni Ramos-Quiroga
Agency: Fondo de Investigación Sanitaria (FIS), Instituto de Salud Carlos III
Funding: 159,720 €
Period: 2022-2025